The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis
Open accessAbstract
OBJECTIVE: Low vitamin D status has been associated with multiple sclerosis (MS) prevalence and risk, but the therapeutic potential of vitamin D in established MS has not been explored. Our aim was to assess the tolerability of high-dose oral vitamin D and its impact on biochemical, immunologic, and clinical outcomes in patients with MS prospectively. METHODS: An open-label randomized prospective controlled 52-week trial matched patients with MS for demographic and disease characteristics, with randomization to treatment or control groups. Treatment patients received escalating vitamin D doses up to 40,000 IU/day over 28 weeks to raise serum 25-hydroxyvitamin D [25(OH)D] rapidly and assess tolerability, followed by 10,000 IU/day (12 weeks), and further downtitrated to 0 IU/day. Calcium (1,200 mg/day) was given throughout the trial. Primary endpoints were mean change in serum calcium at each vitamin D dose and a comparison of serum calcium between groups. Secondary endpoints included 25(OH)D and other biochemical measures, immunologic biomarkers, relapse events, and Expanded Disability Status Scale (EDSS) score. RESULTS: Forty-nine patients (25 treatment, 24 control) were enrolled [mean age 40.5 years, EDSS 1.34, and 25(OH)D 78 nmol/L]. All calcium-related measures within and between groups were normal. Despite a mean peak 25(OH)D of 413 nmol/L, no significant adverse events occurred. Although there may have been confounding variables in clinical outcomes, treatment group patients appeared to have fewer relapse events and a persistent reduction in T-cell proliferation compared to controls. CONCLUSIONS: High-dose vitamin D (approximately 10,000 IU/day) in multiple sclerosis is safe, with evidence of immunomodulatory effects. CLASSIFICATION OF EVIDENCE: This trial provides Class II evidence that high-dose vitamin D use for 52 weeks in patients with multiple sclerosis does not significantly increase serum calcium levels when compared to patients not on high-dose supplementation. The trial, however, lacked statistical precision and the design requirements to adequately assess changes in clinical disease measures (relapses and Expanded Disability Status Scale scores), providing only Class level IV evidence for these outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006) · JAMA · doi:10.1001/jama.296.23.2832 · Cited by 1,897
Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety
Vieth, R. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.5.842 · Cited by 1,500
Self-citationThe urgent need to recommend an intake of vitamin D that is effective
Vieth, R., Bischoff-Ferrari, H., Boucher, B. J., Dawson-Hughes, B., Garland, C. F., Heaney, R. P., Holick, M. F., Hollis, B. W., Lamberg-Allardt, C., McGrath, J. J., et al. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.3.649 · Cited by 684
Self-citationPast exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study
van der Mei, I. A. F., Ponsonby, A.-L., Dwyer, T., Blizzard, L., Simmons, R., Taylor, B. V., Butzkueven, H., & Kilpatrick, T. (2003) · BMJ · doi:10.1136/bmj.327.7410.316 · Cited by 551
Noseworthy, J. H., Ebers, G. C., Vandervoort, M. K., Farquhar, R. E., Yetisir, E., & Roberts, R. (1994) · Neurology · doi:10.1212/wnl.44.1.16 · Cited by 341
Vitamin D as an immune modulator in multiple sclerosis, a review
Smolders, J., Damoiseaux, J., Menheere, P., & Hupperts, R. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.11.014 · Cited by 317
Acheson, E. D., Bachrach, C. A., & Wright, F. M. (1960) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1960.tb08674.x · Cited by 277
25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis
Soilu-Hänninen, M., Airas, L., Mononen, I., Heikkilä, A., Viljanen, M., & Hänninen, A. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1157oa · Cited by 236
Cited by
Vitamin D for health: a global perspective
Hossein-nezhad, A., & Holick, M. F. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.05.011 · Cited by 1,298
The Nonskeletal Effects of Vitamin D: An Endocrine Society Scientific Statement
Rosen, C. J., Adams, J. S., Bikle, D. D., Black, D. M., Demay, M. B., Manson, J. E., Murad, M. H., & Kovacs, C. S. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1000 · Cited by 765
Vitamin D-effects on skeletal and extraskeletal health and the need for supplementation
Wacker, M., & Holick, M. (2013) · Nutrients · doi:10.3390/nu5010111 · Cited by 733
Vitamin D supplementation for prevention of mortality in adults
Bjelakovic, G., Gluud, L. L., Nikolova, D., Whitfield, K., Wetterslev, J., Simonetti, R. G., Bjelakovic, M., & Gluud, C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007470.pub3 · Cited by 695
ESPEN guideline clinical nutrition in neurology
Burgos, R., Bretón, I., Cereda, E., Desport, J. C., Dziewas, R., Genton, L., Gomes, F., Jésus, P., Leischker, A., Muscaritoli, M., et al. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.09.003 · Cited by 571
Metadata
- Authors
- Burton, J. M., Kimball, S., Vieth, R., Bar-Or, A., Dosch, H.-M., Cheung, R., Gagne, D., D'Souza, C., Ursell, M., & O'Connor, P.
- Venue
- Neurology
- Published
- 2010-06-08
- Volume
- 74
- Issue
- 23
- Pages
- 1852-1859
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2106185842
- Cited by
- 360
- References
- 21
- FWCI
- 28.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. https://app.cochat.ai/papers/10.1212/wnl.0b013e3181e1cec2
- The paper
- Burton, J. M., Kimball, S., Vieth, R., Bar-Or, A., Dosch, H.-M., Cheung, R., Gagne, D., D'Souza, C., Ursell, M., & O'Connor, P. (2010). A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. https://doi.org/10.1212/wnl.0b013e3181e1cec2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.